A partnership announced on July 23, 2026, focuses on gene therapy, drug discovery, and translational oncology involving AstraZeneca, Saudi Arabia, Peking University, and Harvard University.
2 reports, 1 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A partnership announced on July 23, 2026, focuses on gene therapy, drug discovery, and translational oncology involving AstraZeneca, Saudi Arabia, Peking University, and Harvard University.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
Saudi Arabia
country in West Asia
-
Peking University
university in Beijing, China
Nothing else this week.
-
Harvard University
private university in Cambridge, Massachusetts
Related events
- Peking University, Bayer, and Acuitas Therapeutics collaborate on basic pharmaceutical research and strengthening gene editing programs.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Petra Hamerlik, who previously worked at AstraZeneca plc, has been appointed as the Chair of Translational Neuro-Oncology at the University of Manchester.